Inсretin-based therapy in patients with type 2 diabetes and chronic kidney disease
https://doi.org/10.14341/2072-0351-6087
Abstract
The program of renoprotection in patients with diabetes mellitus (DM) is based on a conceptual model of development and progressionof diabetic kidney disease, which is the result of combined impact of genetically modulated metabolic and hemodynamic factors. Compensationof carbohydrate metabolism, which is crucial at the clinical debut of nephropathy, becomes problematic at the late stages ofchronic kidney disease (CKD). ADA (American Diabetes Association) and EASD (European Association for the Study of Diabetes)recommendations formalized in a consensus on the treatment of patients with type 2 diabetes (T2D) should only be extrapolated topatients with CKD with great prudence. Incretin-based drugs gain reputation as promising and perspective therapy for metabolic controlin patients with type 2 DM and CKD. There is an obvious need for large-scale, long-term studies involving patients with various severityof renal disease and related complications to assess the potential of this new diabetes therapy trend.
About the Authors
Minara Shamkhalovna Shamkhalova
Endocrinology Research Centre, Moscow
Marina Vladimirovna Shestakova
Endocrinology Research Centre, Moscow
References
1. Шестакова МВ, Дедов ИИ. Сахарный диабет и хроническая болезнь почек. М: МИА; 2009. 482 с.
2. Сахарный диабет: острые и хронические осложнения. Под ред. Дедова ИИ, Шестаковой МВ. М: МИА; 2011. 480 с.
3. NKF-K/DOKI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266.
4. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011 Jul;80(1):17-28. doi: 10.1038/ki.2010.483. Epub 2010 Dec 8.
5. Дедов ИИ, Шестакова МВ, Александров АнА, Галстян ГР, Григорян ОР, Эсаян РМ, Калашников ВЮ, Кураева ТЛ, Липатов ДВ, Майоров АЮ, Петеркова ВА, Смирнова ОМ, Старостина ЕГ, Суркова ЕВ, Сухарева ОЮ, Токмакова АЮ, Шамхалова МШ, Ярек-Мартынова ИР. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (5-й выпуск). Сахарный диабет. 2011;(3 прил.1):4-72.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-986.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 Sep 12;352(9131):837-853.
8. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2560-2572. Epub 2008 Jun 6.
9. Schernthaner G, Ritz E, Schernthaner GH. Strict glycaemic control in diabetic patients with CKD or ESRD: beneficial or deadly? Nephrol Dial Transplant. 2010 Jul;25(7):2044-2047. Epub 2010 Apr 12.
10. Little RR, Tennill AL, Rohlfing C, Wiedmeyer HM, Khanna R, Goel S, Agrawal A, Madsen R, Goldstein DE. Can glycohemoglobin be used to assess glycaemic control in patients with chronic renal failure? Clin Chem. 2002 May;48(5):784-786.
11. Virtue MA, Furne JK, Nuttall FQ, Levitt MD. Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care. 2004 Apr;27(4):931-935.
12. Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, Bello A, James M, Turin TC, Tonelli M; Alberta Kidney Disease Network. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronickidney disease: a population-based cohort study. Arch InternMed. 2011 Nov 28;171(21):1920-1927.
13. Бикбов БТ, Томилина НА. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998-2009 гг. Нефрология и диализ. 2011;13(3):150-264.
14. Drechsler C, Krane V, Ritz E, März W, Wanner C. Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation. 2009 Dec 15;120(24):2421-2428.
15. Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM. Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int. 2006 Oct;70(8):1503-1509. Epub 2006 Aug 30.
16. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006 Aug;29(8):1963-1972.
17. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan;32(1):193-203. Epub 2008 Oct 22.
18. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Diabetes Care. 2012 Jun;35(6):1364-1379. Epub 2012 Apr 19.
19. Kanjanabuch T, Ma LJ, Chen J, Pozzi A, Guan Y, Mundel P, Fogo AB. PPAR-gamma agonist protects podocytes from injury. Kidney Int. 2007 Jun;71(12):1232-1239. Epub 2007 Apr 25.
20. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular disease. N Engl J Med. 2007 Jun 14;356(24):2457-2471. Epub 2007 May 21.
21. Ramirez SP, Albert JM, Blayney MJ, Tentori F, Goodkin DA, Wolfe RA, Young EW, Bailie GR, Pisoni RL, Port FK. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol. 2009 May;20(5):1094-1101. Epub 2009 Apr 8.
22. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009 Apr;32(4):650-657. Epub 2008 Dec 29.
23. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012 Jun;44(4):375-393. doi:10.3109/07853890.2011.560181. Epub 2011 Apr 15.
24. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008 Jan;24(1):275-286.
25. Byetta (exenatide) prescribing information. San Diego CA, Amylin Pharmaceuticals, Inc, 2005; Revised October 2009.
26. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007 Sep;64(3):317-327. Epub 2007 Apr 10.
27. Weise WJ, Sivanandy MS, Block CA, Comi RJ. Exenatideassociated ischemic renal failure. Diabetes Care. 2009 Feb;32(2):e22-23.
28. Victoza (liraglutide) pre scribing information. Princeton , NJ, Novo Nordisk, Inc, January 2010.
29. Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, van Lier JJ, Zdravkovic M, Olsen AK. Metabolism and excretion of the once-daily human glucagonlike peptide-1 analog liraglutide in healthy subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metab Dispos. 2010 Nov;38(11):1944- 1953. Epub 2010 Aug 13.
30. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009 Dec;68(6):898-905.
31. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thøgersen H, Wilken M, Agersø H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000 May 4;43(9):1664-1669.
32. Januvia (sitagliptin) prescribing information. Whitehouse Station, NJ, Merck & Co., Inc, 2009.
33. Onglyza (saxagliptin) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company and Wilmington, DE: AstraZeneca Pharmaceuticals LP, 2009.
34. Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007 Jul;30(7):1862-1864. Epub 2007 Apr 27.
35. Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008 Jul;10(7):545-555. Epub 2008 Jun 1.
36. Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med. 2008 Oct;25(10):1229-1230.
37. Jacobson TA. Toward "pain-free" statin prescribing: Clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc. 2008 Jun;83(6):687-700.
38. Bergman AJ, Cote J, Maes A, Zhao JJ, Roadcap BA, Sun L, Valesky RJ, Yang A, Keymeulen B, Mathijs Z, De Smet M, Laethem T, Davies MJ, Wagner JA, Herman GA. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol. 2009 Apr;49(4):483-488. Epub 2009 Feb 9.
39. Ferreira L, Teixeira-de-Lemos E, Pinto F, Parada B, Mega C, Vala H, Pinto R, Garrido P, Sereno J, Fernandes R, Santos P, Velada I, Melo A, Nunes S, Teixeira F, Reis F. Effect of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm. 2010;2010:592760. Epub 2010 Jun 21.
40. Mega C, de Lemos ET, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, Teixeira F, Reis F. Diabetic nephropathy amelioration by low-dose sitagliptin in an animal model of type 2 diabetes (Zucker Diabetic Fatty Rat). Exp Diabetes Res. 2011;2011:162092. Epub 2011 Nov 30.
41. Odegaard D, Lane J, Haire C. Sitagliptin use in kidney transplant recipients: Effect on immunosuppressant levels. Diabetes. 2008; 58(Suppl 1):A646.
42. He H, Tran P, Yin H, Smith H, Batard Y, Wang L, Einolf H, Gu H, Mangold JB, Fischer V, Howard D. Absorption, metabolism and excretion of vildagliptin, a novel dipeptidyl peptidase -4 inhibitor, in humans. Drug Metab Dispos. 2009 Mar;37(3):536- 544. Epub 2008 Dec 15.
43. Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-weeck randomized placebo-controlled trial. Diabetes Obes Metab. 2011 Oct;13(10):947-954. doi: 10.1111/j.1463-1326.2011.01467.x.
44. Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal insufficiency . Diabetes Obes Metab. 2012 Jun 12. doi: 10.1111/j.1463- 1326.2012.01634.x.
45. European Medicines Agency. Galvus (vilagliptin) - European Public Assessment Report (EPAR). EMA /220510/2012.
46. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, Karyekar CS, Eddington ND, Weir MR, Henrich WL. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther. 2003 May;73(5):427-434.
47. Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I. Saxagliptin improves glycaemic control and is well tolerated in type 2 diabetes and renal impairment. Diabetes Obes Metab. 2011 Jun;13(6):523-532. doi: 10.1111/j.1463-1326.2011.01382.x.
48. Freeman MK. Efficacy and safety of linagliptin (Tradjenta) in adults with type 2 diabetes. P T. 2011 Dec;36(12):807-842.
49. Newman J, McGill JB, Patel S, Friedrich C, Sauce C, Woerle HJ. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment. Diabetologia. 2011; 54(Suppl 1), S333-Abst. 821.
50. Cooper M, von Eynatten M, Emser A, Patel S, Woerle HJ. Efficacy and Safety of Linagliptin in Patients with Type 2 Diabetes with or Without Renal Impairment: Results From a Global Phase 3 Program. American Diabetes Association, 71th Scientific Sessions, San Diego, CA, June 24-28, 2011; 1068-P.
51. Sloan L, Newman J, Sauce C, von Eynatten M, Patel S, Woerle HJ. Safety and Efficacy of Linagliptin in Type 2 Diabetes Patients with Severe Renal Impairment. American Diabetes Association, 71th Scientific Sessions, San Diego, CA, June 24-28, 2011; 413-PP.
Review
For citations:
Shamkhalova M.Sh., Shestakova M.V. Inсretin-based therapy in patients with type 2 diabetes and chronic kidney disease. Diabetes mellitus. 2012;15(3):59-66. (In Russ.) https://doi.org/10.14341/2072-0351-6087
Views:
910
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
